You are here:

Professor Hardev Pandha

Professor of Medical Oncology

Qualifications: MD PhD

Email:
Phone: Work: 01483 68 8602
Room no: 26 PGM 02

Office hours

Mon-Fri 9am-5pm.

Further information

Biography

 

CSST medical oncology                     Royal College of Physicians          Dec 1999

PhD                                                 University of London,                     April 1998

                                                          Imperial College

FRACP                                            Royal Australian College                Feb 1994

                            of Physicians

MRCP(UK)                                       Royal College of Physicians           October 1989

MB ChB                                           University of Birmingham               July 1986

 

Senior Lecturer in Medical Oncology   St George’s, University of London    01/12/00-01/12/05

Senior Registrar Medical Oncology     Royal Marsden Hospital                  01/08/98-01/08/00

Visiting Fellow                                     Stanford University                       01/04/98-01/08/98

Clinical Research Fellow                     Hammersmith Hospital, ICRF         01/09/94-01/04/98

Senior Registrar Medical Oncology     Hammersmith Hospital                    01/07/93-01/09/94

Research Interests

Tumour Immunology

Urological Cancer

Gene Therapy

For further information, please visit our Cancer Research theme page.

Publications

Journal articles

  • Alharbi RA, Pettengell R, Pandha HS, Morgan R. (2012) 'The role of HOX genes in normal hematopoiesis and acute leukemia.'. Leukemia,
    doi: 10.1038/leu.2012.356
    Full text is available at: http://epubs.surrey.ac.uk/744438/

    Abstract

    The homeobox (HOX) genes are a highly conserved family of homeodomain-containing transcription factors that specify cell identity in early development and, subsequently, in a number of adult processes including hematopoiesis. The dysregulation of HOX genes is associated with a number of malignancies including acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL), where they have been shown to support the immortalization of leukemic cells both as chimeric partners in fusion genes and when overexpressed in their wild-type form. This review covers our current understanding of the role of HOX genes in normal hematopoiesis, AML and ALL, with particular emphasis on the similarities and differences of HOX function in these contexts, their hematopoietic downstream gene targets and implications for therapy.Leukemia advance online publication, 8 January 2013; doi:10.1038/leu.2012.356.

  • Morgan R, Boxall A, Simpson GR, Michael A, Pandha HS, Harrington KJ, Gillett C. (2012) 'Targeting the HOX/PBX dimer in breast cancer'. Breast Cancer Research and Treatment, 136 (2), pp. 389-398.
    doi: 10.1007/s10549-012-2259-2
  • Adair RA, Scott KJ, Fraser S, Errington-Mais F, Pandha H, Coffey M, Selby P, Cook GP, Vile R, Harrington KJ, Toogood G, Melcher AA. (2012) 'Cytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cells.'. Int J Cancer,
    doi: 10.1002/ijc.27918
  • Morgan R, Boxall A, Harrington KJ, Simpson GR, Gillett C, Michael A, Pandha HS. (2012) 'Targeting the HOX/PBX dimer in breast cancer.'. Breast Cancer Res Treat, Netherlands: 136 (2), pp. 389-398.
    doi: 10.1007/s10549-012-2259-2
  • Pandha H, Morgan R, Sorensen KD, Orntoft TF, Borre M, Hoyer S, Langley S. (2012) 'Urinary engrailed-2 (EN2) levels predict tumour volume in men undergoing radical prostatectomy for prostate cancer'. BJU International, 110 (6B)
    doi: 10.1111/j.1464-410X.2012.11208.x
  • Pandha H, Sorensen KD, Orntoft TF, Langley S, Hoyer S, Borre M, Morgan R. (2012) 'Urinary engrailed-2 (EN2) levels predict tumour volume in men undergoing radical prostatectomy for prostate cancer.'. BJU Int, England: 110 (6 Pt B), pp. E287-E292.
    doi: 10.1111/j.1464-410X.2012.11208.x
  • Mansfield D, Pencavel T, Kyula JN, Zaidi S, Roulstone V, Thway K, Karapanagiotou L, Khan AA, McLaughlin M, Touchefeu Y, Seth R, Melcher AA, Vile RG, Pandha HS, Harrington KJ. (2012) 'Oncolytic Vaccinia virus and radiotherapy in head and neck cancer.'. Oral Oncol,
    doi: 10.1016/j.oraloncology.2012.07.019
  • Roulstone V, Twigger K, Zaidi S, Pencavel T, Kyula JN, White C, McLaughlin M, Seth R, Karapanagiotou EM, Mansfield D, Coffey M, Nuovo G, Vile RG, Pandha HS, Melcher AA, Harrington KJ. (2012) 'Synergistic cytotoxicity of oncolytic reovirus in combination with cisplatin-paclitaxel doublet chemotherapy.'. Gene Ther,
    doi: 10.1038/gt.2012.68
  • Donnelly O, Vile R, Pandha H, Harrington K, Melcher A. (2012) 'The hitchhiker's guide to virotherapy.'. Oncotarget, United States: 3 (8), pp. 735-736.
  • Tuan J, Pandha H, Corbishley C, Khoo V. (2012) 'Basaloid carcinoma of the prostate: A literature review with case report'. Indian Journal of Urology, 28 (3), pp. 322-324.
    doi: 10.4103/0970-1591.102714
  • Adair RA, Roulstone V, Scott KJ, Morgan R, Nuovo GJ, Fuller M, Beirne D, West EJ, Jennings VA, Rose A, Kyula J, Fraser S, Dave R, Anthoney DA, Merrick A, Prestwich R, Aldouri A, Donnelly O, Pandha H, Coffey M, Selby P, Vile R, Toogood G, Harrington K, Melcher AA. (2012) 'Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients.'. Sci Transl Med, United States: 4 (138)
    doi: 10.1126/scitranslmed.3003578
  • Pulido J, Kottke T, Thompson J, Galivo F, Wongthida P, Diaz RM, Rommelfanger D, Ilett E, Pease L, Pandha H, Harrington K, Selby P, Melcher A, Vile R. (2012) 'Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma'. NATURE PUBLISHING GROUP NATURE BIOTECHNOLOGY, 30 (4), pp. 336-343.
    doi: 10.1038/nbt.2157
  • Karapanagiotou EM, Roulstone V, Twigger K, Ball M, Tanay M, Nutting C, Newbold K, Gore ME, Larkin J, Syrigos KN, Coffey M, Thompson B, Mettinger K, Vile RG, Pandha HS, Hall GD, Melcher AA, Chester J, Harrington KJ. (2012) 'Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies.'. Clin Cancer Res, United States: 18 (7), pp. 2080-2089.
    doi: 10.1158/1078-0432.CCR-11-2181
  • Simpson GR, Horvath A, Annels NE, Pencavel T, Metcalf S, Seth R, Peschard P, Price T, Coffin RS, Mostafid H, Melcher AA, Harrington KJ, Pandha HS. (2012) 'Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer'. BRITISH JOURNAL OF CANCER, 106 (3), pp. 496-507.
    doi: 10.1038/bjc.2011.577
  • Middleton GW, Annels NE, Pandha HS. (2012) 'Are we ready to start studies of Th17 cell manipulation as a therapy for cancer?'. Cancer Immunol Immunother, Germany: 61 (1), pp. 1-7.
    doi: 10.1007/s00262-011-1151-y
  • Pulido J, Kottke T, Thompson J, Galivo F, Diaz RM, Rommelfanger D, Ilett E, Vile R, Pulido J, Wongthida P, Ilett E, Selby P, Melcher A, Vile R, Pease L, Vile R, Pandha H, Harrington K. (2012) 'Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma'. Nature Biotechnology, 30 (4), pp. 337-343.
    doi: 10.1038/nbt.2157
  • Donnelly OG, Errington-Mais F, Steele L, Hadac E, Jennings V, Scott K, Peach H, Phillips RM, Bond J, Pandha H, Harrington K, Vile R, Russell S, Selby P, Melcher AA. (2011) 'Measles virus causes immunogenic cell death in human melanoma.'. Gene Ther,
    doi: 10.1038/gt.2011.205
  • Metcalf S, Pandha HS, Morgan R. (2011) 'Antiangiogenic effects of zoledronate on cancer neovasculature.'. Future Oncol, England: 7 (11), pp. 1325-1333.
    doi: 10.2217/fon.11.113
  • Kottke T, Chester J, Ilett E, Thompson J, Diaz R, Coffey M, Selby P, Nuovo G, Pulido J, Mukhopadhyay D. (2011) 'Precise scheduling of chemotherapy primes VEGF-producing tumors for successful systemic oncolytic virotherapy.'. Mol Ther, United States: 19 (10), pp. 1802-1812.
    doi: 10.1038/mt.2011.147
  • Donnelly OG, Errington-Mais F, Prestwich R, Harrington K, Pandha H, Vile R, Melcher AA. (2011) 'Recent Clinical Experience With Oncolytic Viruses.'. Curr Pharm Biotechnol,
    doi: 10.2174/138920112800958904
  • Kottke T, Errington F, Pulido J, Galivo F, Thompson J, Wongthida P, Diaz RM, Chong H, Ilett E, Chester J, Pandha H, Harrington K, Selby P, Melcher A, Vile R. (2011) 'Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors.'. Nat Med, United States: 17 (7), pp. 854-859.
    doi: 10.1038/nm.2390
  • Hamdan S, Verbeke CS, Fox N, Booth J, Bottley G, Pandha HS, Blair GE. (2011) 'The roles of cell surface attachment molecules and coagulation Factor X in adenovirus 5-mediated gene transfer in pancreatic cancer cells.'. Cancer Gene Ther, England: 18 (7), pp. 478-488.
    doi: 10.1038/cgt.2011.17
  • Gabitass RF, Annels NE, Stocken DD, Pandha HA, Middleton GW. (2011) 'Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13.'. Cancer Immunol Immunother, Germany: 60 (10), pp. 1419-1430.
    doi: 10.1007/s00262-011-1028-0
  • Ilett EJ, Bárcena M, Errington-Mais F, Griffin S, Harrington KJ, Pandha HS, Coffey M, Selby PJ, Limpens RW, Mommaas M, Hoeben RC, Vile RG, Melcher AA. (2011) 'Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralization.'. Clin Cancer Res, United States: 17 (9), pp. 2767-2776.
    doi: 10.1158/1078-0432.CCR-10-3266
  • Morgan R, Boxall A, Bhatt A, Bailey M, Hindley R, Langley S, Whitaker HC, Neal DE, Ismail M, Whitaker H, Annels N, Michael A, Pandha H. (2011) 'Engrailed-2 (EN2): A Tumor Specific Urinary Biomarker for the Early Diagnosis of Prostate Cancer'. AMER ASSOC CANCER RESEARCH CLINICAL CANCER RESEARCH, 17 (5), pp. 1090-1098.
    doi: 10.1158/1078-0432.CCR-10-2410
    Full text is available at: http://epubs.surrey.ac.uk/2751/
  • Steele L, Errington F, Prestwich R, Ilett E, Harrington K, Pandha H, Coffey M, Selby P, Vile R, Melcher A. (2011) 'Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-kappa B mediated and supports innate and adaptive anti-tumour immune priming'. BIOMED CENTRAL LTD MOLECULAR CANCER, 10 Article number ARTN 20
    doi: 10.1186/1476-4598-10-20
  • Middleton GW, Annels NE, Pandha HS. (2011) 'Are we ready to start studies of Th17 cell manipulation as a therapy for cancer?'. Cancer Immunology, Immunotherapy, , pp. 1-7.
    doi: 10.1007/s00262-011-1151-y
  • Gray S, Pandha HS, Michael A, Middleton G, Morgan R. (2011) 'HOX genes in pancreatic development and cancer.'. JOP, Italy: 12 (3), pp. 216-219.
  • Heinemann L, Simpson GR, Boxall A, Kottke T, Relph KL, Vile R, Melcher A, Prestwich R, Harrington KJ, Morgan R, Pandha HS. (2011) 'Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer.'. Biomed Central BMC Cancer, England: 11
    doi: 10.1186/1471-2407-11-221
    Full text is available at: http://epubs.surrey.ac.uk/107390/

    Abstract

    Reovirus type 3 Dearing (T3D) has demonstrated oncolytic activity in vitro, in in vivo murine models and in early clinical trials. However the true potential of oncolytic viruses may only be realized fully in combination with other modalities such as chemotherapy, targeted therapy and radiotherapy. In this study, we examine the oncolytic activity of reovirus T3D and chemotherapeutic agents against human prostate cancer cell lines, with particular focus on the highly metastatic cell line PC3 and the chemotherapeutic agent docetaxel. Docetaxel is the standard of care for metastatic prostate cancer and acts by disrupting the normal process of microtubule assembly and disassembly. Reoviruses have been shown to associate with microtubules and may require this association for efficient viral replication.

  • Kelly ZL, Michael A, Pandha HS, Morgan RG, Butler-Manuel S. (2011) 'HOX genes in ovarian cancer'. Journal of Ovarian Research, 4 (1)
    doi: 10.1186/1757-2215-4-16
    Full text is available at: http://epubs.surrey.ac.uk/711372/

    Abstract

    The HOX genes are a family of homeodomain-containing transcription factors that determine cellular identity during development. Here we review a number of recent studies showing that HOX genes are strongly expressed in ovarian cancer, and that in some cases the expression of specific HOX genes is sufficient to confer a particular identity and phenotype upon cancer cells. We also review the recent advances in elucidating the different functions of HOX genes in ovarian cancer. A literature search was performed using the search terms HOX genes (including specific HOX genes), ovarian cancer and oncogenesis. Articles were accessed through searches performed in ISI Web of Knowledge, PubMed and ScienceDirect. Taken together, these studies have shown that HOX genes play a role in the oncogenesis of ovarian cancer and function in the inhibition of apoptosis, DNA repair and enhanced cell motility. The function of HOX genes in ovarian cancer oncogenesis supports their potential role as prognostic and diagnostic markers, and as therapeutic targets in this disease. © 2011 Kelly et al; licensee BioMed Central Ltd.

  • Kottke T, Ilett E, Thompson J, Diaz R, Vile R, Chester J, Ilett E, Selby P, Melcher A, Vile R, Diaz R, Vile R, Coffey M, Nuovo G, Pulido J, Mukhopadhyay D, Pandha H, Harrington K. (2011) 'Precise scheduling of chemotherapy primes VEGF-producing tumors for successful systemic oncolytic virotherapy'. Molecular Therapy, 19 (10), pp. 1802-1812.
    doi: 10.1038/mt.2011.147
  • Gabitass RF, Annels NE, Stocken DD, Pandha HA, Middleton GW. (2011) 'Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13'. Cancer Immunology, Immunotherapy, 60 (10), pp. 1419-1430.
    doi: 10.1007/s00262-011-1028-0
  • Kelly ZL, Michael A, Butler-Manuel S, Pandha HS, Morgan RG. (2011) 'HOX genes in ovarian cancer.'. J Ovarian Res, England: 4
    doi: 10.1186/1757-2215-4-16
  • Comins C, Spicer J, Protheroe A, Roulstone V, Twigger K, White CM, Vile R, Melcher A, Coffey MC, Mettinger KL, Nuovo G, Cohn DE, Phelps M, Harrington KJ, Pandha HS. (2010) 'REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients with Advanced Cancer'. AMER ASSOC CANCER RESEARCH CLINICAL CANCER RESEARCH, 16 (22), pp. 5564-5572.
    doi: 10.1158/1078-0432.CCR-10-1233
  • Roberts A, Serrano M, Binda E, Vantourout P, Pandha H, Hayday AC. (2010) 'Expansion of Autologous Human V gamma 9V delta 2 T Cells Ex Vivo: Potential for Adoptive T Cell Therapy of Prostate Cancer'. LIPPINCOTT WILLIAMS & WILKINS J IMMUNOTHER, 33 (8), pp. 864-864.
    doi: 10.1097/CJI.0b013e3181f1e08d
  • Annels NE, Denyer M, Pandha H. (2010) 'Increased Myeloid Derived Suppressor Cells in Advanced Prostate Cancer'. LIPPINCOTT WILLIAMS & WILKINS J IMMUNOTHER, 33 (8), pp. 890-891.
    doi: 10.1097/CJI.0b013e3181f1e08d
  • Annels NE, Gabitass RF, Pandha H, Middleton GW. (2010) 'Elevated MDSCs in Pancreatic and Esophago-gastric Cancer Patients Correlates with Poor Prognosis'. LIPPINCOTT WILLIAMS & WILKINS J IMMUNOTHER, 33 (8), pp. 897-897.
    doi: 10.1097/CJI.0b013e3181f1e08d
  • Ismail M, Morgan R, Harrington K, Davies J, Pandha H. (2010) 'Immunoregulatory effects of freeze injured whole tumour cells on human dendritic cells using an in vitro cryotherapy model'. ACADEMIC PRESS INC ELSEVIER SCIENCE CRYOBIOLOGY, 61 (3), pp. 268-274.
    doi: 10.1016/j.cryobiol.2010.09.004
  • Heinemann L, Simpson GR, Annels NE, Vile R, Melcher A, Prestwich R, Harrington KJ, Pandha HS. (2010) 'The Effect of Cell Cycle Synchronization on Tumor Sensitivity to Reovirus Oncolysis'. NATURE PUBLISHING GROUP MOLECULAR THERAPY, 18 (12), pp. 2085-2093.
    doi: 10.1038/mt.2010.189
  • Anesti A-M, Simpson GR, Price T, Pandha HS, Coffin RS. (2010) 'Expression of RNA interference triggers from an oncolytic herpes simplex virus results in specific silencing in tumour cells in vitro and tumours in vivo'. BIOMED CENTRAL LTD BMC CANCER, 10 Article number ARTN 486
    doi: 10.1186/1471-2407-10-486
    Full text is available at: http://epubs.surrey.ac.uk/713427/
  • Lunt C, Barber N, Montgomery A, Kalsi V, Parker T, Michael A, Pandha H, Hindley R. (2010) 'CYTOREDUCTIVE NEPHRECTOMY IN THE TYROKINASE INHIBITOR ERA'. MARY ANN LIEBERT INC J ENDOUROL, 24, pp. A303-A303.
    doi: 10.1089/end.2010.2003.supp
  • Michael A, Relph K, Pandha H. (2010) 'Emergence of potential biomarkers of response to anti-angiogenic anti-tumour agents'. JOHN WILEY & SONS INC INTERNATIONAL JOURNAL OF CANCER, 127 (6), pp. 1251-1258.
    doi: 10.1002/ijc.25389
    Full text is available at: http://epubs.surrey.ac.uk/209783/
  • Pencavel T, Seth R, Hayes A, Melcher A, Pandha H, Vile R, Harrington KJ. (2010) 'Locoregional intravascular viral therapy of cancer: precision guidance for Paris's arrow?'. NATURE PUBLISHING GROUP GENE THERAPY, 17 (8), pp. 949-960.
    doi: 10.1038/gt.2010.48
  • Hingorani M, White CL, Zaidi S, Pandha HS, Melcher AA, Bhide SA, Nutting CM, Syrigos KN, Vile RG, Vassaux G, Harrington KJ. (2010) 'Therapeutic Effect of Sodium Iodide Symporter Gene Therapy Combined With External Beam Radiotherapy and Targeted Drugs That Inhibit DNA Repair'. NATURE PUBLISHING GROUP MOLECULAR THERAPY, 18 (9), pp. 1599-1605.
    doi: 10.1038/mt.2010.120
  • Daniels TR, Neacato II, Rodriguez JA, Pandha HS, Morgan R, Penichet ML. (2010) 'Disruption of HOX activity leads to cell death that can be enhanced by the interference of iron uptake in malignant B cells'. NATURE PUBLISHING GROUP LEUKEMIA, 24 (9), pp. 1555-1565.
    doi: 10.1038/leu.2010.142
  • Harrington KJ, Karapanagiotou EM, Roulstone V, Twigger KR, White CL, Vidal L, Beirne D, Prestwich R, Newbold K, Ahmed M, Thway K, Nutting CM, Coffey M, Harris D, Vile RG, Pandha HS, DeBono JS, Melcher AA. (2010) 'Two-Stage Phase I Dose-Escalation Study of Intratumoral Reovirus Type 3 Dearing and Palliative Radiotherapy in Patients with Advanced Cancers'. AMER ASSOC CANCER RESEARCH CLINICAL CANCER RESEARCH, 16 (11), pp. 3067-3077.
    doi: 10.1158/1078-0432.CCR-10-0054
  • Kottke T, Hall G, Pulido J, Diaz RM, Thompson J, Chong H, Selby P, Coffey M, Pandha H, Chester J, Melcher A, Harrington K, Vile R. (2010) 'Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice'. AMER SOC CLINICAL INVESTIGATION INC JOURNAL OF CLINICAL INVESTIGATION, 120 (5), pp. 1551-1560.
    doi: 10.1172/JCI41431
  • Harrington KJ, Vile RG, Melcher A, Chester J, Pandha HS. (2010) 'Clinical trials with oncolytic reovirus: Moving beyond phase I into combinations with standard therapeutics'. ELSEVIER SCI LTD CYTOKINE & GROWTH FACTOR REVIEWS, 21 (2-3), pp. 91-98.
    doi: 10.1016/j.cytogfr.2010.02.006
  • John J, Ismail M, Riley C, Askham J, Morgan R, Melcher A, Pandha H. (2010) 'Differential effects of Paclitaxel on dendritic cell function'. BIOMED CENTRAL LTD BMC IMMUNOLOGY, 11 Article number ARTN 14
    doi: 10.1186/1471-2172-11-14
  • Morgan R, Plowright L, Harrington KJ, Michael A, Pandha HS. (2010) 'Targeting HOX and PBX transcription factors in ovarian cancer'. BIOMED CENTRAL LTD BMC CANCER, 10 Article number ARTN 89
    doi: 10.1186/1471-2407-10-89
    Full text is available at: http://epubs.surrey.ac.uk/227161/
  • Hingorani M, Spitzweg C, Vassaux G, Newbold K, Melcher A, Pandha H, Vile R, Harrington K. (2010) 'The Biology of the Sodium Iodide Symporter and its Potential for Targeted Gene Delivery'. BENTHAM SCIENCE PUBL LTD CURR CANCER DRUG TAR, 10 (2), pp. 242-267.
    doi: 10.2174/156800910791054194
  • Michael A, John J, Meyer B, Pandha H. (2010) 'Activation and Genetic Modification of Human Monocyte-Derived Dendritic Cells using Attenuated Salmonella typhimurium'. THESCIENTIFICWORLD LTD THESCIENTIFICWORLDJOURNAL, 10, pp. 393-401.
    doi: 10.1100/tsw.2010.37
    Full text is available at: http://epubs.surrey.ac.uk/209786/
  • Pandha HS, Heinemann L, Simpson GR, Melcher A, Prestwich R, Errington F, Coffey M, Harrington KJ, Morgan R. (2009) 'Synergistic Effects of Oncolytic Reovirus and Cisplatin Chemotherapy in Murine Malignant Melanoma'. AMER ASSOC CANCER RESEARCH CLINICAL CANCER RESEARCH, 15 (19), pp. 6158-6166.
    doi: 10.1158/1078-0432.CCR-09-0796
    Full text is available at: http://epubs.surrey.ac.uk/227160/
  • Prestwich RJ, Errington F, Steele LP, Ilett EJ, Morgan RSM, Harrington KJ, Pandha HS, Selby PJ, Vile RG, Melcher AA. (2009) 'Reciprocal Human Dendritic Cell-Natural Killer Cell Interactions Induce Antitumor Activity Following Tumor Cell Infection by Oncolytic Reovirus'. AMER ASSOC IMMUNOLOGISTS JOURNAL OF IMMUNOLOGY, 183 (7), pp. 4312-4321.
    doi: 10.4049/jimmunol.0901074
  • Prestwich RJ, Errington F, Diaz RM, Pandha HS, Harrington KJ, Melcher AA, Vile RG. (2009) 'The Case of Oncolytic Viruses Versus the Immune System: Waiting on the Judgment of Solomon'. MARY ANN LIEBERT INC HUMAN GENE THERAPY, 20 (10), pp. 1119-1132.
    doi: 10.1089/hum.2009.135
  • Ismail M, Morgan R, Harrington K, Davies J, Pandha H. (2009) 'Enhancing prostate cancer cryotherapy using tumour necrosis factor related apoptosis-inducing ligand (TRAIL) sensitisation in an in vitro cryotherapy model'. ACADEMIC PRESS INC ELSEVIER SCIENCE CRYOBIOLOGY, 59 (2), pp. 207-213.
    doi: 10.1016/j.cryobiol.2009.07.008
  • Derhovanessian E, Adams V, Haehnel K, Groeger A, Pandha H, Ward S, Pawelec G. (2009) 'Pretreatment frequency of circulating IL-17(+)CD4(+) T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients'. WILEY-BLACKWELL INTERNATIONAL JOURNAL OF CANCER, 125 (6), pp. 1372-1379.
    doi: 10.1002/ijc.24497
  • Prestwich RJ, Ilett EJ, Errington F, Diaz RM, Steele LP, Kottke T, Thompson J, Galivo F, Harrington KJ, Pandha HS, Selby PJ, Vile RG, Melcher AA. (2009) 'Immune-Mediated Antitumor Activity of Reovirus Is Required for Therapy and Is Independent of Direct Viral Oncolysis and Replication'. AMER ASSOC CANCER RESEARCH CLINICAL CANCER RESEARCH, 15 (13), pp. 4374-4381.
    doi: 10.1158/1078-0432.CCR-09-0334
  • Ismail M, Bokaee S, Davies J, Harrington KJ, Pandha H. (2009) 'Inhibition of the aquaporin 3 water channel increases the sensitivity of prostate cancer cells to cryotherapy'. NATURE PUBLISHING GROUP BRITISH JOURNAL OF CANCER, 100 (12), pp. 1889-1895.
    doi: 10.1038/sj.bjc.6605093
  • Pandha H, Melcher A, Harrington K, Vile R. (2009) 'Oncolytic Viruses: Time to Compare, Contrast, and Combine?'. NATURE PUBLISHING GROUP MOLECULAR THERAPY, 17 (6), pp. 934-935.
    doi: 10.1038/mt.2009.86
  • Ilett EJ, Prestwich RJ, Kottke T, Errington F, Thompson JM, Harrington KJ, Pandha HS, Coffey M, Selby PJ, Vile RG, Melcher AA. (2009) 'Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity'. NATURE PUBLISHING GROUP GENE THERAPY, 16 (5), pp. 689-699.
    doi: 10.1038/gt.2009.29
  • Pandha H, D'Ambrosio C, Heenan S, Hyde N, Di Palma S, Nutting C, Relph K, Harrington K. (2009) 'Indium-labelled Autologous Dendritic Cells Migrate to Local Lymph Nodes after Intratumoural Injection in Head and Neck Cancer Patients'. ELSEVIER SCIENCE LONDON CLINICAL ONCOLOGY, 21 (4), pp. 363-364.
    doi: 10.1016/j.clon.2008.12.002
  • Michael A, Syrigos K, Pandha H. (2009) 'Prostate cancer chemotherapy in the era of targeted therapy'. NATURE PUBLISHING GROUP PROSTATE CANCER AND PROSTATIC DISEASES, 12 (1), pp. 13-16.
    doi: 10.1038/pcan.2008.32
    Full text is available at: http://epubs.surrey.ac.uk/209787/
  • Horvath A, Simpson GR, Coffin RS, Mostafid H, Pandha H. (2009) 'NOVEL INTRAVESICAL THERAPY FOR NON MUSCLE INVASIVE BLADDER CANCER: COMBINATION OF A FUSOGENIC GLYCOPROTEIN, PRO-DRUG ACTIVATION AND ONCOLYTIC HERPES SIMPLEX VIRUS'. ELSEVIER SCIENCE BV EUR UROL SUPPL, 8 (4), pp. 196-196.
    doi: 10.1016/S1569-9056(09)60309-2
  • Prestwich RJ, Scott KJ, Brown J, Harnden P, Whelan P, Cartledge J, O'Donnell D, Pandha HS, Selby PJ, Banks RE, Merrick AE, Melcher AA. (2009) 'The feasibility of establishing a programme of adjuvant autologous vaccination for renal cell carcinoma'. WILEY-BLACKWELL PUBLISHING, INC BJU INTERNATIONAL, 103 (6), pp. 740-746.
    doi: 10.1111/j.1464-410X.2008.08113.x
  • Plowright L, Harrington KJ, Pandha HS, Morgan R. (2009) 'HOX transcription factors are potential therapeutic targets in non-small-cell lung cancer (targeting HOX genes in lung cancer)'. NATURE PUBLISHING GROUP BRITISH JOURNAL OF CANCER, 100 (3), pp. 470-475.
    doi: 10.1038/sj.bjc.6604857
  • Koropouli E, Manolopoulus L, Pandha H, Syrigos KN. (2009) 'The biological role of mTOR in the pathogenesis of solid tumors: An overview'. Current Enzyme Inhibition, 5 (1), pp. 51-65.
    doi: 10.2174/157340809787314274
  • Pandha H, Melcher A, Vile R, Harrington K, Vile R. (2009) '5th international meeting on replicating oncolytic virus therapeutics Banff, Alberta, Canada, 18-22 March 2009'. Molecular Therapy, 17 (6), pp. 934-935.
    doi: 10.1038/mt.2009.86
  • Agrawal VK, Copeland KM, Barbachano Y, Rahim A, Seth R, White CL, Hingorani M, Nutting CM, Kelly M, Harris P, Pandha H, Melcher AA, Vile RG, Porter C, Harrington KJ. (2009) 'Microvascular free tissue transfer for gene delivery: in vivo evaluation of different routes of plasmid and adenoviral delivery'. NATURE PUBLISHING GROUP GENE THERAPY, 16 (1), pp. 78-92.
    doi: 10.1038/gt.2008.140
  • Yap TA, Brunetto A, Pandha H, Harrington K, de Bono JS. (2008) 'Reovirus therapy in cancer: has the orphan virus found a home?'. INFORMA HEALTHCARE EXPERT OPINION ON INVESTIGATIONAL DRUGS, 17 (12), pp. 1925-1935.
    doi: 10.1517/13543780802533401
  • Hingorani M, White CL, Merron A, Peerlinck I, Gore ME, Slade A, Scott SD, Nutting CM, Pandha HS, Melcher AA, Vile RG, Vassaux G, Harrington KJ. (2008) 'Inhibition of Repair of Radiation-Induced DNA Damage Enhances Gene Expression from Replication-Defective Adenoviral Vectors'. AMER ASSOC CANCER RESEARCH CANCER RESEARCH, 68 (23), pp. 9771-9778.
    doi: 10.1158/0008-5472.CAN-08-1911
  • Prestwich RJ, Errington F, Ilett EJ, Morgan RSM, Scott KJ, Kottke T, Thompson J, Morrison EE, Harrington KJ, Pandha HS, Selby PJ, Vile RG, Melcher AA. (2008) 'Tumor Infection by Oncolytic Reovirus Primes Adaptive Antitumor Immunity'. AMER ASSOC CANCER RESEARCH CLINICAL CANCER RESEARCH, 14 (22), pp. 7358-7366.
    doi: 10.1158/1078-0432.CCR-08-0831
  • Vidal L, Pandha HS, Yap TA, White CL, Twigger K, Vile RG, Melcher A, Coffey M, Harrington KJ, DeBono JS. (2008) 'A Phase I Study of Intravenous Oncolytic Reovirus Type 3 Dearing in Patients with Advanced Cancer'. AMER ASSOC CANCER RESEARCH CLINICAL CANCER RESEARCH, 14 (21), pp. 7127-7137.
    doi: 10.1158/1078-0432.CCR-08-0524
  • Alamara C, Karapanagiotou EM, Tourkantonis I, Xyla V, Maurer CC, Lykourinas M, Pandha H, Syrigos KN. (2008) 'Renal oncocytoma: a case report and short review of the literature.'. Eur J Intern Med, Netherlands: 19 (7), pp. e67-e69.
    doi: 10.1016/j.ejim.2008.03.003
  • Shears L, Plowright L, Harrington K, Pandha HS, Morgan R. (2008) 'Disrupting the Interaction Between HOX and PBX Causes Necrotic and Apoptotic Cell Death in the Renal Cancer Lines CaKi-2 and 769-P'. ELSEVIER SCIENCE INC JOURNAL OF UROLOGY, 180 (5), pp. 2196-2201.
    doi: 10.1016/j.juro.2008.07.018
  • Prestwich RJ, Harrington KJ, Pandha HS, Vile RG, Melcher AA, Errington F. (2008) 'Oncolytic viruses: a novel form of immunotherapy'. EXPERT REVIEWS EXPERT REVIEW OF ANTICANCER THERAPY, 8 (10), pp. 1581-1588.
    doi: 10.1586/14737140.8.10.1581
  • Comins C, Heinemann L, Harrington K, Melcher A, De Bono J, Pandha H. (2008) 'Reovirus: Viral therapy for cancer 'as nature intended''. ELSEVIER SCIENCE LONDON CLINICAL ONCOLOGY, 20 (7), pp. 548-554.
    doi: 10.1016/j.clon.2008.04.018
  • Errington F, White CL, Twigger KR, Rose A, Scott K, Steele L, Ilett LJ, Prestwich R, Pandha HS, Coffey M, Selby P, Vile R, Harrington KJ, Melcher AA. (2008) 'Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma'. NATURE PUBLISHING GROUP GENE THERAPY, 15 (18), pp. 1257-1270.
    doi: 10.1038/gt.2008.58
  • Harrington KJ, Melcher A, Vassaux G, Pandha HS, Vile RG. (2008) 'Exploiting synergies between radiation and oncolytic viruses'. THOMSON SCIENTIFIC CURRENT OPINION IN MOLECULAR THERAPEUTICS, 10 (4), pp. 362-370.
  • Hingorani M, White CL, Zaidi S, Merron A, Peerlinck I, Gore ME, Nutting CM, Pandha HS, Melcher AA, Vile RG, Vassaux G, Harrington KJ. (2008) 'Radiation-mediated up-regulation of gene expression from replication-defective adenoviral vectors: Implications for sodium iodide symporter gene therapy'. AMER ASSOC CANCER RESEARCH CLINICAL CANCER RESEARCH, 14 (15), pp. 4915-4924.
    doi: 10.1158/1078-0432.CCR-07-4049
  • White CL, Twigger KR, Vidal L, De Bono JS, Coffey M, Heinemann L, Morgan R, Merrick A, Errington F, Vile RG, Melcher AA, Pandha HS, Harrington KJ. (2008) 'Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial'. NATURE PUBLISHING GROUP GENE THERAPY, 15 (12), pp. 911-920.
    doi: 10.1038/gt.2008.21
  • Pandha HS, Protheroe A, Wylie J, Parker C, Chambers J, Bell S, Munzert G. (2008) 'An open label phase II trial of BI 2536, a novel Plk1 inhibitor, in patients with metastatic hormone refractory prostate cancer (HRPC)'. AMER SOC CLINICAL ONCOLOGY JOURNAL OF CLINICAL ONCOLOGY, 26 (15)
  • Errington F, Steele L, Prestwich R, Harrington KJ, Pandha HS, Vidal L, de Bono J, Selby P, Coffey M, Vile R, Melcher A. (2008) 'Reovirus activates human dendritic cells to promote innate antitumor immunity'. AMER ASSOC IMMUNOLOGISTS JOURNAL OF IMMUNOLOGY, 180 (9), pp. 6018-6026.
  • Havranek EG, Labarthe M-C, Ward S, Anderson CJ, Whelan MA, Pandha H. (2008) 'A novel murine model of allogeneic vaccination against renal cancer'. BLACKWELL PUBLISHING BJU INTERNATIONAL, 101 (9), pp. 1165-1169.
    doi: 10.1111/j.1464-410X.2008.07532.x
  • White CL, Menghistu T, Twigger KR, Searle PF, Bhide SA, Vile RG, Melcher AA, Pandha HS, Harrington KJ. (2008) 'Escherichia coli nitroreductase plus CB1954 enhances the effect of radiotherapy in vitro and in vivo'. NATURE PUBLISHING GROUP GENE THERAPY, 15 (6), pp. 424-433.
    doi: 10.1038/sj.gt.3303081
  • Twigger K, Vidal L, White CL, De Bono JS, Bhide S, Coffey M, Thompson B, Vile RG, Heinemann L, Pandha HS, Errington F, Melcher AA, Harrington KJ. (2008) 'Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy'. AMER ASSOC CANCER RESEARCH CLINICAL CANCER RESEARCH, 14 (3), pp. 912-923.
    doi: 10.1158/1078-0432.CCR-07-1400
  • Qiao J, Wang H, Kottke T, White C, Twigger K, Diaz RM, Thompson J, Selby P, de Bono J, Melcher A, Pandha H, Coffey M, Vile R, Harrington K. (2008) 'Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus'. AMER ASSOC CANCER RESEARCH CLINICAL CANCER RESEARCH, 14 (1), pp. 259-269.
    doi: 10.1158/1078-0432.CCR-07-1510
  • Prestwich RJ, Errington F, Harrington KJ, Pandha HS, Selby P, Melcher A. (2008) 'Oncolytic viruses: do they have a role in anti-cancer therapy?'. Clin Med Oncol, New Zealand: 2, pp. 83-96.
  • Gore ME, Nutting CM, Pandha HS, Melcher AA, Vile RG, Harrington KJ. (2008) 'T-cell responses to survivin in cancer patients undergoing radiation therapy'. Clinical Cancer Research, 14 (15), pp. 4883-4883.
    doi: 10.1158/1078-0432.CCR-07-4462
  • Papaetis GS, Karapanagiotou LM, Pandha H, Syrigos KN. (2008) 'Targeted therapy for advanced renal cell cancer: Cytokines and beyond'. BENTHAM SCIENCE PUBL LTD CURRENT PHARMACEUTICAL DESIGN, 14 (22), pp. 2229-2251.
    doi: 10.2174/138161208785740153
  • Harris D, Vidal L, Melcher A, Newbold K, Anthony A, Karavasilis V, Agarwal R, White C, Twigger K, Coffey M, Mettinger K, Thompson B, Pandha H, De-Bono J, Harrington K. (2007) 'A Phase I study to evaluate the feasibility, safety and biological effects of intratumoural administration of wild-type Reovirus (REOLYSIN (R)) in combination with radiation in patients with advanced malignancies.'. AMER ASSOC CANCER RESEARCH MOLECULAR CANCER THERAPEUTICS, 6 (12), pp. 3458S-3458S.
  • Plowright L, Shears L, Pandha H, Morgan R. (2007) 'Disrupting the interaction between Hox and PBX causes apoptotic cell death and reduces in vivo proliferation of a non-small cell lung cancer model'. AMER ASSOC CANCER RESEARCH MOLECULAR CANCER THERAPEUTICS, 6 (12), pp. 3504S-3504S.
  • Michael A, Politi E, Havranek E, Corbishley C, Karapanagiotou L, Anderson C, Relph K, Syrigos KN, Pandha H. (2007) 'Prognostic significance of erythropoietin expression in human renal cell carcinoma'. BLACKWELL PUBLISHING BJU INTERNATIONAL, 100 (2), pp. 291-294.
    doi: 10.1111/j.1464-410X.2007.06978.x
  • Morgan R, Pirard PM, Shears L, Sohal J, Pettengell R, Pandha HS. (2007) 'Antagonism of HOX/PBX dimer formation blocks the in vivo proliferation of melanoma'. AMER ASSOC CANCER RESEARCH CANCER RESEARCH, 67 (12), pp. 5806-5813.
    doi: 10.1158/0008-5472.CAN-06-4231
  • Lord R, Nair S, Schache A, Spicer J, Somaihah N, Khoo V, Pandha H. (2007) 'Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: A phase II study'. ELSEVIER SCIENCE INC JOURNAL OF UROLOGY, 177 (6), pp. 2136-2140.
    doi: 10.1016/j.juro.2007.01.143
    Full text is available at: http://epubs.surrey.ac.uk/227159/
  • Pandha H, Rigg A, John J, Lemoine N. (2007) 'Loss of expression of antigen-presenting molecules in human pancreatic cancer and pancreatic cancer cell lines'. BLACKWELL PUBLISHING CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 148 (1), pp. 127-135.
    doi: 10.1111/j.1365-2249.2006.03289.x
  • Dalgleish A, Pandha H. (2007) 'Tumor antigens as surrogate markers and targets for therapy and vaccines'. ELSEVIER ACADEMIC PRESS INC ADVANCES IN CANCER RESEARCH, VOL 96, 96, pp. 175-190.
    doi: 10.1016/S0065-230X(06)96009-6
  • Hu JCC, Coffin RS, Davis CJ, Graham NJ, Groves N, Guest PJ, Harrington KJ, James ND, Love CA, McNeish I, Medley LC, Michael A, Nutting CM, Pandha HS, Shorrock CA, Simpson J, Steiner J, Steven NM, Wright D, Coombes RC. (2006) 'A phase I study of OncoVEX(GM-CSF), a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor'. AMER ASSOC CANCER RESEARCH CLINICAL CANCER RESEARCH, 12 (22), pp. 6737-6747.
    doi: 10.1158/1078-0432.CCR-06-0759
  • Morgan R, Fairfax B, Pandha HS. (2006) 'Calcium insensitivity of FA-6, a cell line derived from a pancreatic cancer associated with humoral hypercalcemia, is mediated by the significantly reduced expression of the Calcium Sensitive Receptor transduction component p38 MAPK'. BIOMED CENTRAL LTD MOLECULAR CANCER, 5 Article number ARTN 51
    doi: 10.1186/1476-4598-5-51
    Full text is available at: http://epubs.surrey.ac.uk/2595/
  • Pandha H, Birchall L, Meyer B, Wilson N, Relph K, Anderson C, Harrington K. (2006) 'Antitumor effects of aminobisphosphonates on renal cell carcinoma cell lines'. ELSEVIER SCIENCE INC JOURNAL OF UROLOGY, 176 (5), pp. 2255-2261.
    doi: 10.1016/j.juro.2006.07.053
    Full text is available at: http://epubs.surrey.ac.uk/209784/
  • Yap TA, Vidal L, Pandha H, Spicer J, Digue L, Coffey M, Thompson B, Kaye SB, Harrington KJ, De-Bono JS. (2006) 'A phase I study of wild-type reovirus, which selectively replicates in cells expressing activated Ras, administered intravenously to patients with advanced cancer'. PERGAMON-ELSEVIER SCIENCE LTD EJC SUPPLEMENTS, 4 (12), pp. 108-108.
    doi: 10.1016/S1359-6349(06)70353-6
  • Chowdhury S, Pandha H. (2006) 'Targeting renal cell carcinoma'. ELSEVIER SCIENCE LONDON CLINICAL ONCOLOGY, 18 (7), pp. 511-512.
    doi: 10.1016/j.clon.2006.06.006
  • Quatan N, Meyer B, Bailey M, Pandha H. (2006) 'Persistently high levels of immunosuppressive cytokines in patients after radical prostatectomy'. NATURE PUBLISHING GROUP PROSTATE CANCER AND PROSTATIC DISEASES, 9 (4), pp. 420-425.
    doi: 10.1038/sj.pcan.4500899
  • Spicer J, Plunkett T, Somaiah N, Chan S, Kendall A, Bolunwu N, Pandha H. (2005) 'Phase II study of oral capecitabine in patients with hormone-refractory prostate cancer'. NATURE PUBLISHING GROUP PROSTATE CANCER AND PROSTATIC DISEASES, 8 (4), pp. 364-368.
    doi: 10.1038/sj.pcan.4500821

Conference papers

  • Kelly Z, Pandha H, Morgan R, Michael A. (2012) 'HXR9 AND PARP INHIBITION -A NOVEL THERAPEUTIC IN OVARIAN CANCER'. OXFORD UNIV PRESS ANNALS OF ONCOLOGY, Vienna, AUSTRIA: 37th Congress of the European-Society-for-Medical-Oncology (ESMO) 23, pp. 325-325.
  • Kelly Z, Pandha H, Madhuri K, Morgan R, Michael A. (2012) 'HOX GENE EXPRESSION IN OVARIAN CANCER'. OXFORD UNIV PRESS ANNALS OF ONCOLOGY, Vienna, AUSTRIA: 37th Congress of the European-Society-for-Medical-Oncology (ESMO) 23, pp. 68-68.
  • Ravaud A, Motzer RJ, Pandha H, Staehler M, George DJ, Pantuck A, Patel A, Gerletti P, Chen L, Patard J. (2012) 'SUNITINIB TREATMENT OF RENAL ADJUVANT CANCER (S-TRAC): A RANDOMIZED, DOUBLE-BLIND, PHASE III STUDY OF SUNITINIB VS. PLACEBO IN SUBJECTS AT HIGH RISK OF RECURRENT RENAL CELL CARCINOMA (RCC)'. OXFORD UNIV PRESS ANNALS OF ONCOLOGY, Vienna, AUSTRIA: 37th Congress of the European-Society-for-Medical-Oncology (ESMO) 23, pp. 292-293.
  • Kottke T, Donnelly O, Boisgerault N, Diaz R, Thompson J, Chester J, Pandha H, Harrington K, Melcher A, Vile R. (2012) 'Characterization of the Mechanisms of Tumor Dormancy and Recurrence Following Front Line Immuno-, Viro- or Suicide Gene-, Therapy'. NATURE PUBLISHING GROUP MOLECULAR THERAPY, Philadelphia, PA: 15th Annual Meeting of the American-Society-of-Gene-and-Cell-Therapy (ASGCT) 20, pp. S268-S268.
  • Horvath A, Simpson GR, Coffin RS, Mostafid AH, Pandha H. (2011) 'Update on a novel intravesical therapy for non muscle invasive bladder cancer: Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic herpes simplex virus'. WILEY-BLACKWELL BRITISH JOURNAL OF SURGERY, Royal Free Hosp, London, ENGLAND: Annual Meeting of the Society-of-Academic-and-Research-Surgeons 98 (6), pp. E2-E2.
  • Ismail MI, Bokaee S, Annels N, Davies J, Pandha H. (2011) 'Predominance of CD8 T cell infiltration coincides with reciprocal reduction in regulatory T cells following prostate cryotherapy'. WILEY-BLACKWELL BRITISH JOURNAL OF SURGERY, Royal Coll Surgery, Dublin, IRELAND: Annual Meeting of the Society-of-Academic-and-Research-Surgery 98, pp. 48-48.
  • Michael A, Zylstra J, Pandha H. (2011) 'The sun study-a biobank of sequential blood samples from patients with prostate cancer'. WILEY-BLACKWELL BRITISH JOURNAL OF SURGERY, Royal Coll Surgery, Dublin, IRELAND: Annual Meeting of the Society-of-Academic-and-Research-Surgery 98, pp. 50-50.
  • Roberts A, Serrano M, Vantourout P, Dieli F, Pandha H, Hayday AC. (2010) 'Expansion of autologous human V gamma 9V delta 2 T cells ex vivo: potential for adoptive T cell therapy of prostate cancer'. WILEY-BLACKWELL PUBLISHING, INC IMMUNOLOGY, Liverpool, ENGLAND: Annual Congress of the British-Society-for-Immunology 131, pp. 119-119.
  • Binda E, Perez SM, Pandha H, Eberl M, Hayday A. (2010) 'Monitoring the immunological effects of bisphosphonates in different treatment scenarios'. WILEY-BLACKWELL PUBLISHING, INC IMMUNOLOGY, Liverpool, ENGLAND: Annual Congress of the British-Society-for-Immunology 131, pp. 117-117.
  • Annels NE, Riley C, Bokaee S, Denyer M, Simpson GR, Pandha H. (2010) 'EN2: A Novel Immunotherapeutic Target for Melanoma'. LIPPINCOTT WILLIAMS & WILKINS JOURNAL OF IMMUNOTHERAPY, 33 (8), pp. 891-891.
  • Horvath A, Simpson GR, Coffin RS, Mostafid H, Pandha H. (2010) 'NOVEL INTRAVESICAL THERAPY FOR NON MUSCLE INVASIVE BLADDER CANCER USING A GENETICALLY MODIFIED ONCOLYTIC HERPES SIMPLEX VIRUS'. ELSEVIER SCIENCE BV EUROPEAN UROLOGY SUPPLEMENTS, 9 (6), pp. 646-646.
  • Ismail M, Morgan R, Davies J, Pandha H. (2009) 'Inhibition of the aquaporin water channels (AQPs) increases the sensitivity of DU145 cells to cryotherapy'. WILEY-BLACKWELL PUBLISHING, INC BJU INTERNATIONAL, Glasgow, SCOTLAND: Annual Meeting of the British-Association-of-Urological-Surgeons 103, pp. 21-21.
  • Rudman SM, Comins C, Mukherji D, Coffey M, Mettinger K, Protheroe A, Harrington KJ, Pandha H, Spicer JF. (2009) 'Results of a phase I study to evaluate the feasibility, safety, and biological effects of intravenous administration of wild-type reovirus with docetaxel to patients with advanced malignancies'. AMER SOC CLINICAL ONCOLOGY JOURNAL OF CLINICAL ONCOLOGY, Orlando, FL: 45th Annual Meeting of the American-Society-of-Clinical-Oncology 27 (15)
  • Karapanagiotou E, Pandha HS, Hall G, Chester J, Melcher A, Coffey M, de Bono J, Gore ME, Nutting CM, Harrington KJ. (2009) 'Phase I/II trial of oncolytic reovirus (Reolysin) in combination with carboplatin/paclitaxel in patients (pts) with advanced solid cancers'. AMER SOC CLINICAL ONCOLOGY JOURNAL OF CLINICAL ONCOLOGY, Orlando, FL: 45th Annual Meeting of the American-Society-of-Clinical-Oncology 27 (15)
  • Ismail M, Kevin H, Morgan R, Davies J, Pandha H. (2009) 'ENHANCING PROSTATE CANCER CRYOTHERAPY USING TUMOUR NECROSIS FACTOR RELATED APOPTOSIS-INDUCING LIGAND (TRAIL) SENSITISATION IN A NOVEL IN VITRO MODEL'. ELSEVIER SCIENCE INC JOURNAL OF UROLOGY, Chicago, IL: 104th Annual Meeting of the American-Urological-Association 181 (4), pp. 189-190.
  • Ismail M, Morgan R, Davies J, Pandha H. (2009) 'INHIBITION OF THE AQUAPORIN WATER CHANNELS INCREASES THE SENSITIVITY OF PROSTATE CANCER CELLS TO FREEZING INJURY.'. ELSEVIER SCIENCE INC JOURNAL OF UROLOGY, Chicago, IL: 104th Annual Meeting of the American-Urological-Association 181 (4), pp. 185-185.
  • Comins C, Spicer J, Protheroe A, Mukherji D, Coffey M, Thompson B, Harrington K, Pandha H. (2008) 'A Phase I Study to Evaluate Systemic Wild-type Reovirus (REOLYSIN)(R) in Combination With Docetaxel in Patients With Advanced Malignancies'. LIPPINCOTT WILLIAMS & WILKINS JOURNAL OF IMMUNOTHERAPY, San Diego, CA: 23rd Annual Scientific Meeting of the International-Society-for-Biological-Therapy-of-Cancer 31 (9), pp. 951-951.
  • Karapanagiotou E, Pandha H, Hall G, Chester J, Melcher A, De Bono J, Gore M, Nutting C, Harrington K. (2008) 'Phase I Trial of Oncolytic Reovirus (Reolysin) in Combination With Carboplatin/Paclitaxel in Patients With Advanced Solid Cancers'. LIPPINCOTT WILLIAMS & WILKINS JOURNAL OF IMMUNOTHERAPY, San Diego, CA: 23rd Annual Scientific Meeting of the International-Society-for-Biological-Therapy-of-Cancer 31 (9), pp. 952-952.
  • Heinemann L, Kottke T, Vile R, Coffey MC, Harrington K, Melcher A, Pandha HS. (2008) 'Synergistic Anti-Tumor Activity of Oncolytic Reovirus and Docetaxel in a PC-3 Prostate Cancer Mouse Model'. LIPPINCOTT WILLIAMS & WILKINS JOURNAL OF IMMUNOTHERAPY, San Diego, CA: 23rd Annual Scientific Meeting of the International-Society-for-Biological-Therapy-of-Cancer 31 (9), pp. 951-952.
  • Simpson GR, Horvath A, Harrington K, Coffin RS, Pandha H. (2008) 'Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer'. PERGAMON-ELSEVIER SCIENCE LTD EJC SUPPLEMENTS, Geneva, SWITZERLAND: 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 6 (12), pp. 97-98.
    doi: 10.1016/S1359-6349(08)72238-9
  • Heinemann L, Simpson G, Harrington K, Melcher A, Coffey MC, Pandha HS. (2008) 'Synergistic anti-tumour activity of oncolytic Reovirus and cisplatin in a B16.F10 mouse melanoma model'. PERGAMON-ELSEVIER SCIENCE LTD EJC SUPPLEMENTS, Geneva, SWITZERLAND: 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 6 (12), pp. 99-99.
    doi: 10.1016/S1359-6349(08)72242-0
  • Ismail M, Morgan R, Davies J, Pandha H. (2008) 'Immunoregulatory effects of cryo-treated prostate cancer cells on human dendritic cells using a novel in vitro cryotherapy model'. ELSEVIER SCIENCE INC JOURNAL OF UROLOGY, Orlando, FL: 103rd Annual Meeting of the American-Urological-Association 179 (4), pp. 48-48.
    doi: 10.1016/S0022-5347(08)60144-5
  • Balls G, Quatan N, Michael A, Lancashire L, Adams V, Hoffman B, Pfirschke C, Russell N, Whelan M, Pandha H. (2007) 'Immunological response patterns correlate with clinical outcome after allogeneic vaccination in hormone resistant prostate cancer metastatic to bone'. LIPPINCOTT WILLIAMS & WILKINS JOURNAL OF IMMUNOTHERAPY, Boston, MA: 22nd Annual Scientific Meeting of the International-Society-for-Biological-Therapy-of-Cancer 30 (8), pp. 891-891.
  • Meyer B, Denyer M, Morgan R, Pandha H. (2007) 'Cellular effects of phosphoramide mustard, the active metabolite of cyclophosphamide, on naturally-occuring human CD4(+) CD25(+) regulatory T cells'. LIPPINCOTT WILLIAMS & WILKINS JOURNAL OF IMMUNOTHERAPY, Boston, MA: 22nd Annual Scientific Meeting of the International-Society-for-Biological-Therapy-of-Cancer 30 (8), pp. 887-887.
  • Ismail M, Ahmed S, Laing R, Nigam R, Langley S, Pandha H, Davies J. (2007) 'Antibody immunity to prostate cancer specific antigen in the serum of patients having cryotherapy or brachytherapy treatment compared to healthy volunteers'. BLACKWELL PUBLISHING BJU INTERNATIONAL, Glasgow, SCOTLAND: Annual Meeting of the British-Association-of-Urological-Surgeons 99, pp. 47-48.
  • Verbeke CS, Hamdan S, Booth J, Pandha HS, Blair GE. (2006) 'Limited expression of the Coxsackie and Adenovirus Receptor in pancreatic cancer may reduce suitability of adenoviral gene therapy'. JOHN WILEY & SONS LTD JOURNAL OF PATHOLOGY, Manchester, ENGLAND: 190th Meeting of the Pathological-Society-of-Great-Britain-and-Ireland 210, pp. 2-2.
  • Vidal L, Pandha H, Spicer J, Harrington KJ, Allen S, Leader D, Coffey M, Thompson B, Kaye S, De-Bono J. (2006) 'A phase I study of reolysin given intravenously to patients with advanced malignancies.'. AMER SOC CLINICAL ONCOLOGY JOURNAL OF CLINICAL ONCOLOGY, Atlanta, GA: 42nd Annual Meeting of the American-Society-of-Clinical-Oncology 24 (18), pp. 136S-136S.
  • Vidal L, Twigger K, White C, Coffey M, Thompson B, De-Bono J, Pandha HS, Melcher A, Kaye S, Harrington KJ. (2005) 'Reovirus enhances radiation cytotoxicity in vitro and in vivo.'. AMER ASSOC CANCER RESEARCH CLINICAL CANCER RESEARCH, Philadelphia, PA: AACR/NCI/EORTC International Conference on Molecular Targets and Cancer Therapeutics 11 (24), pp. 9005S-9006S.
  • Vidal L, Pandha H, Harrington K, Fong P, Shaw H, Barrett M, Leader D, White C, Twigger K, Coffey M, Thompson B, Kaye S, De-Bono J. (2005) 'A phase I study of a wild-type reovirus (Reolysin) given intravenously to patients with advanced malignancies.'. AMER ASSOC CANCER RESEARCH CLINICAL CANCER RESEARCH, Philadelphia, PA: AACR/NCI/EORTC International Conference on Molecular Targets and Cancer Therapeutics 11 (24), pp. 9106S-9107S.

Books

  • Pandha HS, Relph K, Harrington K. (2008) Treatment of Cancer 5th Edition Chapter Gene Therapy. 5th Edition.
  • Pandha HS, Harrington KJ, Vile RG. (2008) Viral Therapy of Cancer. John Wiley

Book chapters

  • Pandha HS, Harrington KJ, Vile RG. (2008) 'Poxviruses as immunomodulatory cancer therapeutics.'. in (ed.) Viral Therapy of Cancer